GSK preps for vac­cine R&D ex­pan­sion, 200 hires for new glob­al hub

A year and a half af­ter Glax­o­SmithK­line set in mo­tion its big flip with No­var­tis, trad­ing can­cer drugs for vac­cines, the UK phar­ma gi­ant has fol­lowed through on plans to cre­ate a glob­al vac­cine R&D cen­ter in Rockville, MD, well with­in the or­bit of the NIH and FDA reg­u­la­tors.

This new fa­cil­i­ty comes with the lat­est in vac­cine tech, says GSK, and will house up to 450 sci­en­tists when it’s ful­ly op­er­a­tional. Get­ting there will take an­oth­er $50 mil­lion in­vest­ment over the next two years, along with some 200 new hires.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER